Abstract |
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.
|
Authors | A J M Ferreri, S Dell'Oro, M Foppoli, M Bernardi, A A Brandes, A Tosoni, M Montanari, M Balzarotti, M Spina, F Ilariucci, F Zaja, C Stelitano, F Bobbio, G Corazzelli, L Baldini, M Ponzoni, P Picozzi, F Caligaris Cappio, M Reni |
Journal | Neurology
(Neurology)
Vol. 66
Issue 9
Pg. 1435-8
(May 09 2006)
ISSN: 1526-632X [Electronic] United States |
PMID | 16682682
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article)
|
Chemical References |
- Cytarabine
- Thiotepa
- Methotrexate
- Idarubicin
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Central Nervous System Neoplasms
(drug therapy, mortality, radiotherapy)
- Combined Modality Therapy
- Cranial Irradiation
(adverse effects)
- Cytarabine
(administration & dosage, adverse effects)
- Female
- Hematologic Diseases
(chemically induced)
- Humans
- Idarubicin
(administration & dosage, adverse effects)
- Life Tables
- Lymphoma, Non-Hodgkin
(drug therapy, mortality, radiotherapy)
- Male
- Meningeal Neoplasms
(drug therapy, mortality, radiotherapy)
- Methotrexate
(administration & dosage, adverse effects)
- Middle Aged
- Radiotherapy, Adjuvant
(adverse effects)
- Remission Induction
- Stroke
(etiology)
- Survival Analysis
- Thiotepa
(administration & dosage, adverse effects)
|